ARS Pharmaceuticals (SPRY) Cash from Investing Activities (2020 - 2026)

ARS Pharmaceuticals has reported Cash from Investing Activities for 7 years, with the latest figure at $27.8 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 4.38% year-over-year to $27.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.5 million (up 180.99% YoY) and the FY2025 annual result came in at $56.8 million, up 153.5% from the prior year.
• Cash from Investing Activities grew to $27.8 million in Q1 2026 per SPRY's latest filing, from $24.1 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $48.6 million in Q2 2025 and troughed at -$111.5 million in Q1 2023.
• A 5-year average of -$6.4 million and a median of -$22000.0 in 2022 frame the typical range for Cash from Investing Activities.
• The widest YoY moves for Cash from Investing Activities: up 204509.09% in 2023, down 531071.43% in 2023.
• Over 5 years, Cash from Investing Activities stood at -$126000.0 in 2022, then soared by 20765.87% to $26.0 million in 2023, then slumped by 490.8% to -$101.8 million in 2024, then jumped by 123.7% to $24.1 million in 2025, then climbed by 15.25% to $27.8 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $27.8 million, $24.1 million, and -$45.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.